From 1 April 2017, NHS providers and commissioners can be reimbursed via NHS England for specified cost-saving, outcomes-based innovations. This event, hosted by the NHS Innovation Accelerator (NIA), is an opportunity to learn more about the medtech devices and digital platforms available to procure via the new Innovation and Technology Tariff (ITT).
The ‘Improving outcomes, cutting costs’ events will specifically showcase the five NIA innovations available to procure via central funding from 1 April 2017. NHS England will also be introducing the ITT and providing insight as to how it will work.This event includes presentations from NHS England and your local Academic Health Science Networks (AHSNs), Eastern AHSN, West Midlands AHSN and East Midlands AHSN, with opportunities for Q&A and access to further information and resources.
Why should I attend?
- Access some of the country’s best evidence-based innovations and be reimbursed by NHS England
- Meet the NIA Fellows who have developed these innovations and see first-hand how they work
- Learn how these innovations have improved efficiencies, benefitted patients and secured cost savings across other NHS organisations
- Find out how to replicate these benefits across your organisation
These innovations include:
- MyCOPD: Online self-management system for COPD proven to reduce acute hospital admissions (saving CCGs £370,000 per year), NHS spending, and improve the quality of patients’ lives.
- The Non-Injectable Arterial Connector (NIC): Patient safety device which stops medication being accidentally given through the arterial lines used to monitor the blood of patients in ICUs and operating theatres. Improves safety while offering regional savings of over £156,500 per year.
- PneuX Prevention System: Patient safety device designed to stop ventilator-associated pneumonia (VAP), affecting some 20,000 patients each year, around a third of whom will die, with each episode costing the NHS between £10,000 and £20,000.
- Episcissors-60: Guiding mediolateral episiotomy evidenced to minimise the risk of obstetric anal sphincter injury (OASIS), delivering savings through reduced litigation costs, elective caesarean sections and repair (£1,625 per patient).
- AliveCor’s Kardia: Mobile ECG device for the identification and measurement of atrial fibrillation (AF) - the cause of between 25,000-35,000 strokes in the UK per year
- NeoTract's UroLift® System: A revolutionary, minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue out of the way so it no longer blocks the urethra.
Who should attend?
The following across local clinical commissioning groups and provider organisations should attend: